Top in cardiology: New agents to lower triglycerides; FDA OKs extravascular ICD system
Click Here to Manage Email Alerts
After years of failed attempts to develop therapies meant to reduce elevated triglycerides, novel agents are now showing promise in the management of hypertriglyceridemia, a speaker said.
“There is a pressing need to unravel the complexities of the interaction between triglycerides and other CV risk factors,” Michael D. Shapiro, DO, Fred M. Parrish Professor of Cardiology and Molecular Medicine and director of the Center for Prevention and Cardiovascular Disease at Wake Forest University School of Medicine, told Healio. “On the clinical front, developing novel, effective and safe triglyceride-lowering therapies is a priority.”
It was the top story in cardiology last week.
In another top story, the FDA approved Medtronic’s extravascular implantable cardioverter-defibrillator system, which is intended to treat tachycardia that may cause sudden cardiac arrest.
Read these and more top stories in cardiology below:
After many failed trials, novel therapeutics may finally tackle high triglycerides
After years of failed clinical trials with agents to lower severely elevated triglycerides, emerging therapeutics hold promise for effectively addressing hypertriglyceridemia and reducing associated CV risks, a speaker reported at the Cardiometabolic Health Congress. Read more.
FDA approves extravascular ICD system with anti-tachycardia pacing
Medtronic announced it received FDA approval for its extravascular implantable cardioverter-defibrillator and defibrillation lead to treat tachycardia that may cause sudden cardiac arrest. Read more.
Early diagnosis, treatment intensification essential to improve diabetes outcomes
Interventions that prevent or delay the onset of type 2 diabetes are critically important, and early diagnosis and treatment intensification can improve outcomes and increase lifespan, according to a speaker. Read more.
VIDEO: Low-dose colchicine can address residual inflammatory risk
In this Healio video exclusive, Paul M. Ridker, MD, MPH, discusses the use of low-dose colchicine to target inflammation in patients who remain at high CVD risk despite controlled LDL. Watch here.
In heart failure hospitalization, benefits of sacubitril/valsartan largest in left ventricular ejection fraction below normal
Entresto (sacubitril/valsartan, Novartis) was associated with reduced natriuretic peptides and lower risk for CV death and heart failure hospitalization across the spectrum of ejection fraction, particularly in those with EF below 60%, a speaker reported. Read more.